Actively Recruiting
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
Led by Peking University Third Hospital · Updated on 2025-01-24
50
Participants Needed
1
Research Sites
232 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in orbital neoplasms, and compared with 18F-FDG PET/CT.
CONDITIONS
Official Title
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with suspected or newly diagnosed orbital neoplasms confirmed by MRI, CT, or pathology report
- Patients scheduled for both 18F-FDG and 18F-AlF-FAPI PET/CT scans
- Patients able to provide informed consent or assent according to clinical research ethics guidelines
You will not qualify if you...
- Pregnancy
- Breastfeeding
- Inability or unwillingness to provide written informed consent by the participant, parent, or legal representative
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dept. of Nuclear Medicine, Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
Actively Recruiting
Research Team
H
Hui Li
CONTACT
L
Lingge Suo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here